Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc. - Common Stock
(NQ:
BEAM
)
24.14
+0.49 (+2.05%)
Delayed Quote
Updated: 11:15 AM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
February 24, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
↗
February 22, 2025
Via
Benzinga
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
↗
February 15, 2025
Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.
Via
Benzinga
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
↗
February 14, 2025
Via
Benzinga
(BEAM) - Analyzing Beam Therapeutics's Short Interest
↗
January 31, 2025
Via
Benzinga
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews
↗
January 29, 2025
Via
Benzinga
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
January 30, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
January 23, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
January 13, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views
↗
November 06, 2024
Via
Benzinga
Beam Therapeutics's Earnings: A Preview
↗
November 04, 2024
Via
Benzinga
Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)
↗
September 11, 2024
Via
Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
↗
December 20, 2024
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Via
Investor's Business Daily
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From
Beam Therapeutics
Via
GlobeNewswire
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
↗
August 22, 2024
Via
Benzinga
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
↗
December 09, 2024
Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.
Via
Benzinga
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
December 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
December 07, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
December 06, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
December 04, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
↗
November 26, 2024
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Via
Benzinga
Topics
Artificial Intelligence
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
↗
November 25, 2024
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.
Via
Benzinga
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
November 12, 2024
From
Beam Therapeutics
Via
GlobeNewswire
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
↗
November 06, 2024
Via
Benzinga
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
↗
November 05, 2024
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency
Via
Benzinga
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
November 05, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
October 29, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
↗
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
